Novolog Pharm-Up 1966 Ltd (NVLG) - Total Liabilities

Latest as of December 2025: ILA1.78 Billion ILA ≈ $4.77 Million USD

Based on the latest financial reports, Novolog Pharm-Up 1966 Ltd (NVLG) has total liabilities worth ILA1.78 Billion ILA (≈ $4.77 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of Novolog Pharm-Up 1966 Ltd's assets are long-term investments to see how much of total assets are deployed in long-term investments.

Novolog Pharm-Up 1966 Ltd - Total Liabilities Trend (2014–2025)

This chart illustrates how Novolog Pharm-Up 1966 Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see NVLG total assets.

Novolog Pharm-Up 1966 Ltd Competitors by Total Liabilities

The table below lists competitors of Novolog Pharm-Up 1966 Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Global Lights Acquisition Corp Ordinary Shares NASDAQ:GLACF	USA	$2.99 Million
Hongli Group Inc. Ordinary Shares NASDAQ:HLP	USA	$14.36 Million
Flexopack Société Anonyme Commercial and Industrial Plastics Company AT:FLEXO	Greece	€86.08 Million
Global Lights Acquisition Corp Ordinary Shares NASDAQ:GLAC	USA	$2.99 Million
Sirios Resources Inc. V:SOI	Canada	CA$6.42 Million
Red Star Macalline Group Corporation Ltd F:3S5	Germany	€68.62 Billion
Charlton Aria Acquisition Corporation Class A Ordinary Shares NASDAQ:CHAR	USA	$3.11 Million
ALi Corp TW:3041	Taiwan	NT$1.20 Billion

Liability Composition Analysis (2014–2025)

This chart breaks down Novolog Pharm-Up 1966 Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Novolog Pharm-Up 1966 Ltd net asset quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.91	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	4.98	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.83	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Novolog Pharm-Up 1966 Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Novolog Pharm-Up 1966 Ltd (2014–2025)

The table below shows the annual total liabilities of Novolog Pharm-Up 1966 Ltd from 2014 to 2025.

Year	Total Liabilities	Change
2025-12-31	ILA1.78 Billion ≈ $4.77 Million	-33.00%
2024-12-31	ILA2.65 Billion ≈ $7.12 Million	+10.97%
2023-12-31	ILA2.39 Billion ≈ $6.41 Million	+21.29%
2022-12-31	ILA1.97 Billion ≈ $5.29 Million	+6.15%
2021-12-31	ILA1.86 Billion ≈ $4.98 Million	-1.73%
2020-12-31	ILA1.89 Billion ≈ $5.07 Million	+0.23%
2019-12-31	ILA1.89 Billion ≈ $5.06 Million	+15.70%
2018-12-31	ILA1.63 Billion ≈ $4.37 Million	-5.22%
2017-12-31	ILA1.72 Billion ≈ $4.61 Million	+18.42%
2016-12-31	ILA1.45 Billion ≈ $3.89 Million	-5.48%
2015-12-31	ILA1.54 Billion ≈ $4.12 Million	+24.78%
2014-12-31	ILA1.23 Billion ≈ $3.30 Million	--

About Novolog Pharm-Up 1966 Ltd

TA:NVLG Israel Medical Distribution

Market Cap

$97.11 Million

ILA36.22 Billion ILA

Market Cap Rank

#19378 Global

#249 in Israel

Share Price

ILA70.90

Change (1 day)

-0.42%

52-Week Range

ILA66.80 - ILA137.60

All Time High

ILA337.91